Information Provided By: 
Fly News Breaks for December 16, 2016
RGEN
Dec 16, 2016 | 10:05 EDT
Stephens analyst Drew Jones raised his price target for Repligen to $37 from $32, saying he views the company's acquisition of TangenX "quite favorably," as it is yet another technology that is well positioned to benefit from the industry's move toward single use/disposable technologies. Further, the analyst thinks the potential synergies brought about from the deal will prove significant. He reiterates an Overweight rating on Repligen's shares.
News For RGEN From the Last 2 Days
There are no results for your query RGEN
